Insulet Appoints Tracey H. Wielinski as VP, Global

Insulet Appoints Tracey H. Wielinski as VP, Global
Regulatory/Clinical Affairs and Quality Assurance 
BEDFORD, MA -- (Marketwire) -- 01/23/13 --  Insulet Corporation
(NASDAQ: PODD), the leader in tubeless insulin pump technology with
its OmniPod(R) Insulin Management System, today announced the
appointment of Tracey H. Wielinski as Vice President, Global
Regulatory/Clinical Affairs and Quality Assurance. Ms. Wielinski
brings two decades of experience in quality assurance, regulatory and
clinical affairs across a wide range of products in the healthcare
industry, including in diabetes devices.  
"Tracey is a highly accomplished quality assurance and regulatory
affairs executive and we are very pleased to welcome her to Insulet's
management team," said Duane DeSisto, President and Chief Executive
Officer of Insulet. "Demand for the easy-to-use OmniPod insulin pump
continues to grow around the world. Tracey's successful track record
in global quality assurance, as well as her expertise in regulatory
and clinical affairs, will be an asset to Insulet as we continue to
advance our technology."  
Most recently, Ms. Wielinski served as President and CEO of Qualtra
Consulting, a medical device consulting firm specializing in
regulatory and clinical affairs and quality system management. From
2008 to 2011, she was with ElectroSonics Medical, serving as Vice
President, Clinical and Regulatory Affairs. Previously, Ms. Wielinski
was with DX Tech, where she was Vice President, Regulatory Affairs
and Quality Assurance. Her prior experience includes roles as Vice
President, Regulatory Affairs and Quality Assurance at Rapid Micro
Biosystems and Vice President, Corporate Quality and Compliance and
Chief Compliance Officer for Oscient Pharmaceuticals. From 1997 to
2004, she held a variety of progressive QARA management roles at
Abbott Laboratories/Medisense Products, Biomec, Inc. and Steris Corp.
Ms. Wielinski holds a B.A. in Biology and Communications from the
University of Toledo, and a M.S. in Health Product Regulation from
Regis College. 
About Insulet Corporation 
 Insulet Corporation (NASDAQ: PODD) is an
innovative medical device company dedicated to making the lives of
people with diabetes easier. Through its OmniPod Insulin Management
System, Insulet seeks to expand the use of insulin pump therapy among
people with insulin-dependent diabetes. The OmniPod is a
revolutionary and easy-to-use tubeless insulin pump that features
just two parts and fully-automated cannula insertion. Insulet's
subsidiary, Neighborhood Diabetes, is a leading distributor for
diabetes products and supplies, delivered through a high touch
customer service model. Founded in 2000, Insulet Corporation is based
in Bedford, Mass.  
Forward-Looking Statements 
 This press release contains
forward-looking statements within the meaning of the federal
securities laws, including the expected closing date of this
offering. These forward-looking statements are based on Insulet's
current expectations and beliefs concerning future developments and
their potential effects on it. There can be no assurance that future
developments affecting it will be those that it has anticipated.
These forward-looking statements involve a number of risks,
uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties described in the
section entitled "Risk Factors" in Insulet's Annual Report on Form
10-K for the year ended December 31, 2011 and Item 1A in Insulet's
Quarterly Report on Form 10-Q for the quarter ended September 30,
2012, and in its other filings from time to time filed with the
Securities and Exchange Commission. Should one or more of these risks
or uncertainties materialize, or should any of its assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking
statements. 
Contact:
Stephanie Marks for Insulet Corporation
ir@insulet.com
877-PODD-IR1 (877-763-3471)